Evotec SE
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christian Wojczewski
- Full Time Employees
- 4,766
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Essener Bogen 7 Hamburg Germany 22419
- IPO Date
- Feb 5, 2004
- CIK
- 0001412558
- Website
- evotec.com
- Similar Companies
- Business
- Evotec SE (EVO) is a life science company that pioneers drug discovery and development through integrated R&D solutions, AI-driven platforms, and advanced technologies for pharmaceutical and biotechnology partners worldwide. Founded in 1993 and headquartered in Hamburg, Germany, the company offers drug discovery services including target identification, hit identification, medicinal chemistry, ADME-Tox screening, in vitro and in vivo pharmacology, biomarker discovery, and data science analytics utilizing artificial intelligence and machine learning; preclinical development encompassing formulation science, process development, predictive safety, and investigational new drug enablement; biologics solutions via Just – Evotec Biologics featuring continuous manufacturing platforms like J.POD for protein therapeutics design, development, clinical supply, and commercial-scale production; and modalities spanning small molecules, biotherapeutics, cell therapies, and induced pluripotent stem cell-based disease modeling across therapeutic areas such as oncology, neurology, metabolic diseases, infectious diseases, immunology, and cardiovascular conditions. Evotec operates globally with facilities in Europe, the United States, and partnerships extending to Asia, serving top 20 pharma companies, over 800 biotechs, academic institutions, and venture capitalists through flexible models including standalone services, fully integrated programs, and long-term alliances with partners like Bristol Myers Squibb, Bayer, Sanofi, Novo Nordisk, Pfizer, and the CHDI Foundation. Recent developments include the extension of its neuroscience and targeted protein degradation collaboration with Bristol Myers Squibb yielding performance-based payments exceeding US$100 million in 2025; new multi-year research partnerships with Novo Nordisk for cell therapies and Pfizer for metabolic and infectious diseases research; advancement of multiple co-owned assets into phase II clinical trials; and a landmark November 2025 agreement with Sandoz for the sale of Just – Evotec Biologics EU in Toulouse plus an indefinite license to its continuous manufacturing technology, potentially generating over US$650 million in payments including US$350 million upfront, future milestones, and royalties on up to ten biosimilars targeting a US$90 billion market, enabling a sharper focus on asset-light biologics technology provision.
Evotec Appoints Rui Wang as Head of Global In Silico and AI
Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Evotec Receives Grants to Advance Tuberculosis Treatment
Evotec Announces New Nomination to Board of Directors
Evotec SE to Announce First Quarter 2026 Results on May 6, 2026
Evotec Announces Chief Financial Officer Transition
Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer
Evotec SE (EVO) Q4 2025 Earnings Call Transcript
Evotec vows to further engage with investor MAK, who demanded change
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer
Evotec (EVO) to Release Quarterly Earnings on Wednesday
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript
Moving iMage Transforms Eight Screen Santa Fe Theater Complex for EVO Entertainment with Cutting-Edge Laser Projection and Digital Sound Systems, including an EVX Enhanced Viewing Experience Auditorium
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction